Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.54 |
| ▸ | TTK | P33981 | 6/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17801052 | 0.92 | TTK (0.53) | MAP3K5TTKMAPK8CSNK1DMAPK1 | |
| SCHEMBL8257261 | 0.91 | MAP3K5 (0.65) | MAP3K5TTKMAPK8CSNK1DMAPK1 | |
| SCHEMBL8258671 | 0.88 | MAPK1 (0.62) | MAP3K5TTKCSNK1DMAPK1MAP2K4 | |
| SCHEMBL5378166 | 0.87 | MAPK1 (0.66) | MAP3K5TTKMAPK8CSNK1DMAPK1 | |
| SCHEMBL5378125 | 0.87 | CSNK1D (0.56) | MAP3K5TTKMAPK8CSNK1DMAPK1 | |
| SCHEMBL5380115 | 0.86 | MAPK1 (0.56) | MAP3K5TTKMAPK8CSNK1DMAPK1 | |
| SCHEMBL8437375 | 0.85 | MAPK1 (0.57) | MAP3K5TTKMAPK8CSNK1DMAPK1 | |
| SCHEMBL8252515 | 0.85 | DYRK1A (0.56) | MAP3K5MAPK8CSNK1DERN1MAPK10 | |
| SCHEMBL8258720 | 0.85 | LRRK2 (0.52) | MAP3K5TTKMAPK8CSNK1DMAPK1 | |
| SCHEMBL5387167 | 0.84 | MAP3K5 (0.53) | MAP3K5TTKMAPK8CSNK1DMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016089977-A1 | SUBSTITUTED INDAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2016-06-09 | — | — | WO | claimed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | claimed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | claimed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| WO-2016089977-A1 | SUBSTITUTED INDAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION (US) | 2016-06-09 | — | — | WO | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAP3K5 7/4885TTK 1198/4885MAPK8 26/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | MAP3K5 2520/4885TTK 2139/4885MAPK8 3017/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | MAP3K5 32/4885TTK 714/4885MAPK8 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.